Live Evaluations

Optimizing The Patient Skin Cancer Journey With Gene Expression Profiling

About

Optimizing The Patient Skin Cancer Journey With Gene Expression Profiling

This activity is supported by an educational grant from Castle Biosciences.

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Discuss the role of gene expression profiling for the management of skin cancers

  • Describe how to integrate gene expression profiling for cutaneous melanoma and SCC to inform risk- and appropriate management decisions

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
Laura
Laura Ferris, MD, PhD

Professor and Director of Clinical Trials, Dermatology
University of Pittsburgh
Pittsburgh, PA

Darrell
Darrell Rigel, MD, MS

Clinical Professor of Dermatology 
Director, Melanoma Surveillance Clinic 
Mount Sinai Icahn School of Medicine, New York, NY 
Adjunct Professor, UT Southwestern Medical School 
Consultant Dermatologist, Cooper Clinic, Dallas, TX

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

CONFLICTS OF INTEREST/DISCLOSURES

In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

Darrell S. Rigel, MD, MS

Grant/Research Support: Castle Biosciences, SciBASE

Consultant: DermTech, Ferndale Laboratories, Inc., SciBase, VYNE Therapeutics 

Speakers’ Bureau or Honoraria: Castle Biosciences

Advisory Board: Almirall, Beiersdorf, Inc., Castle Biosciences, Johnson and Johnson 

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.


Dermsquared

The leading platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2023 dermsquared | All Rights Reserved